Holen Sie sich die Stockscreener-App
0.5015
7.30%
-0.0395
Schlusskurs vom Vortag:
$0.541
Offen:
$0.86
24-Stunden-Volumen:
1.26M
Relative Volume:
7.49
Marktkapitalisierung:
$17.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.33M
KGV:
-0.347
EPS:
-1.4452
Netto-Cashflow:
$-42.44M
1W Leistung:
-3.45%
1M Leistung:
-19.13%
6M Leistung:
-30.71%
1J Leistung:
-84.66%
1-Tages-Spanne:
$0.4732
$0.88
1-Wochen-Bereich:
$0.4732
$0.88
52-Wochen-Spanne:
$0.276
$4.9902
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
1.86 | 2.83B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.89 | 388.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.88 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.45 | 348.74M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
48.03 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-08-15 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Skye drops obesity program, combines with Redx to form Fibrx - AllSci
Skye Bioscience Q2 Loss Narrows Sharply on Lower R&D Spending - Minichart
SKYE: Merger creates Fibrx, a well-funded fibrosis company advancing RXC008 for Crohn's disease - TradingView
Skye Bioscience to Be Acquired by Redx Pharma in $264.5M Nasdaq-Listed Merger - Minichart
SKYE: Merger creates a well-funded fibrosis company advancing RXC008 for Crohn's disease, with phase II data due 2029 - TradingView
Form 8K Skye Bioscience Inc For: 14 August By Investing.com - Investing.com India
Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com - Investing.com UK
Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line - TradingView
Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView
Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding - Stock Titan
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - marketscreener.com
Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Skye Bioscience Inc (SKYE) Stock News Today - tradingkey.com
SKYE Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Skye Bioscience2026 Funding Rounds & List of Investors - Tracxn
SKYE Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Skye Bioscience Inc (SKYE) Cash Flow - TradingKey
Skye Bioscience Inc (SKYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SKYE|Skye Bioscience Inc|Price:0.625|Chg%:-0.027 - TradingKey
Skye Bioscience, Inc. Revenue Breakdown – LSX:A3ES4X - TradingView
Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Skye Bioscience Inc (SKYE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Skye Bioscience Market Sentiment - Benzinga España
TradingKey - TradingKey
Skye Bioscience Inc (SKYE) Institutional Confidence - TradingKey
Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims - TipRanks
Skye Bioscience (SKYE) Edges Higher as Stock Holds Above Key Support at $0.63Wide Range Bar - dars.gov.et
Skye Bioscience (SKYE) Slides Toward Support as Bearish Pressure PersistsJelly Roll Trade - dars.gov.et
SKYE Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Skye Bioscience (SKYE) Nudges Higher as Biotech Sector Finds FootingVWAP Deviation - dars.gov.et
SKYE Q1 2026 Earnings: Clinical-Stage Biotech Reports EPS Miss Amid Ongoing Pipeline Development - dars.gov.et
Skye Bioscience Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Pipeline DevelopmentQuarterly Earnings - dars.gov.et
SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Acceleration Picks - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, In - The National Law Review
Skye Bioscience, Inc. Financial Disclosures & SEC Filings - TradingView
Price to earnings forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Enterprise value to revenue forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Price to book forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Enterprise value to EBIT forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Price to sales forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Skye Bioscience, Inc. Actuals & Estimates (NASDAQ:SKYE) - TradingView
Skye Bioscience, Inc. Actuals & Estimates (FWB:09R) - TradingView
SKYE Forecast — Price Target — Prediction for 2027 - TradingView
Skye Bioscience Moves Listing to Nasdaq Capital Market - The Globe and Mail
Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall - TradingView
Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices - Stock Titan
Skye Bioscience Inc (SKYE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Skye Bioscience, Inc. Stock 12‑Month Price Target Cut to $7.33, Implies 937% Upside - TradingView
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):